Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 431 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: In Situ Neoplasms Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

NCT05463796
View directory record Official record
Conditions
Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
Interventions
Samples
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Not applicable Interventional Results available

MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery

NCT00749931
View directory record Official record
Conditions
Breast Cancer
Interventions
MarginProbe, Lumpectomy
Device · Procedure
Lead sponsor
Dune Medical Devices
Industry
Eligibility
18 Years to 90 Years · Female only
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
18
States / cities
Costa Mesa, California • Los Angeles, California • Newport Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Oxybutynin Chloride in Managing Hot Flashes

NCT02961790
View directory record Official record
Conditions
Breast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes, Lobular Breast Carcinoma In Situ, No Evidence of Disease
Interventions
Oxybutynin Chloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
Peoria, Illinois • Urbana, Illinois • Cedar Rapids, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

NCT02993159
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Interventions
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Chicago, Illinois • Edgewood, Kentucky • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

NCT04387461
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer
Interventions
CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside
Biological · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
La Jolla, California • Orange, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)

NCT00652080
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
API 31510
Drug
Lead sponsor
BPGbio
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Hot Springs, Arkansas • San Diego, California • Buffalo Grove, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 20, 2026, 5:31 PM EDT
Not listed Phase 1 Interventional

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

NCT00109655
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Bladder Neoplasms
Interventions
Oncolytic adenovirus (serotype 5) - CG0070
Biological
Lead sponsor
Cell Genesys
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
8
States / cities
Phoenix, Arizona • San Francisco, California • Billings, Montana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2008 · Synced Oct 20, 2026, 5:31 PM EDT
Not listed Phase 2 Interventional

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers

NCT06409195
View directory record Official record
Conditions
Non-Melanoma Skin Cancers
Interventions
SM-020 1% Gel
Drug
Lead sponsor
DermBiont, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Not applicable Interventional

Regenerative Tissue Matrix for Breast Reconstruction

NCT01027637
View directory record Official record
Conditions
Breast Cancer
Interventions
5 mm vessel clips
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 6, 2013 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Not applicable Interventional

S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

NCT01097278
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
Interventions
cholecalciferol, placebo
Dietary Supplement · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 50 Years · Female only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
360
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 230 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 20, 2026, 5:31 PM EDT
Recruiting Phase 2 Interventional

5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer

NCT06961955
View directory record Official record
Conditions
Breast Cancer, Invasive Carcinoma of Breast, Ductal Breast Carcinoma in Situ
Interventions
Radiation Therapy
Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Not applicable Interventional

Educational Interventions for Patients With DCIS

NCT00148655
View directory record Official record
Conditions
DCIS
Interventions
Decision Board
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
25 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

The Effects of Lycopene on High Risk Prostatic Tissue

NCT01443026
View directory record Official record
Conditions
Intraepithelial Prostatic Neoplasia, Prostatic Neoplasms
Interventions
Lycopene 30mg, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 20, 2026, 5:31 PM EDT
Recruiting Phase 3 Interventional

Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy

NCT01185132
View directory record Official record
Conditions
Breast Cancer
Interventions
accelerated partial breast irradiation - 3D-conformal planning, accelerated partial breast irradiation - IMRT planning
Radiation
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
40 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Boulder, Colorado • Lakewood, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Not applicable Interventional Results available

Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making

NCT03766009
View directory record Official record
Conditions
Breast Cancer Stage 0, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
Usual Care, Web-based decision aid
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
56
States / cities
Dublin, California • Emeryville, California • Martinez, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 5:31 PM EDT
Recruiting Not applicable Interventional

CONFIRM: Magnetic Resonance Guided Radiation Therapy

NCT04368702
View directory record Official record
Conditions
Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma, Larynx Cancer, Bladder Cancer
Interventions
Viewray MRIdian® Linac
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Not applicable Interventional Results available

Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®

NCT01448447
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma in Situ
Interventions
Mammosite ML
Device
Lead sponsor
Mercy Research
Other
Eligibility
45 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Early Phase 1 Interventional

Broccoli Sprout Extract in Treating Patients With Breast Cancer

NCT01753908
View directory record Official record
Conditions
Ductal Breast Carcinoma, Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative, Estrogen Receptor Positive, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Postmenopausal, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
Broccoli Sprout Extract, Laboratory Biomarker Analysis, Pharmacological Study, Placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 20, 2026, 5:31 PM EDT
Withdrawn No phase listed Observational

Ductal Lavage in Assessing Women With Early Breast Cancer or at High Risk of Developing Breast Cancer and Who Are Eligible For Tamoxifen Therapy

NCT00083044
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 25, 2012 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Not applicable Interventional

THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence

NCT06388304
View directory record Official record
Conditions
Breast Cancer, DCIS
Interventions
THRIVE Online PAT Program
Behavioral
Lead sponsor
Joanna Arch
Other
Eligibility
21 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 20, 2026, 5:31 PM EDT
Withdrawn Phase 1 Interventional

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

NCT04109092
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
E7766
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Gilbert, Arizona • Los Angeles, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Not applicable Interventional Results available

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

NCT01293032
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis, Gene Expression Analysis, Systemic Chemotherapy, Tamoxifen Citrate, Aromatase Inhibition Therapy
Procedure · Other · Genetic + 1 more
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Charlotte, North Carolina • Greensboro, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 20, 2026, 5:31 PM EDT
Completed Phase 2Phase 3 Interventional

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

NCT00406068
View directory record Official record
Conditions
Bladder Neoplasms
Interventions
Mycobacterial cell wall-DNA complex
Drug
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • San Diego, California • New Britain, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 20, 2026, 5:31 PM EDT
Completed No phase listed Observational

Markers of Response to Intravesical Bladder Cancer Therapy

NCT01007058
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 20, 2026, 5:31 PM EDT